You are here

Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glioblastoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after
surgery (or biopsy) and treatment with radiotherapy (conventional fractionated
external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)

- Must have past biopsy samples available for central pathology review

- Must have evidence on Gd-MRI of progressive/recurrent disease

- Must have measurable disease on Gd-MRI obtained within 14 days prior to start of study
treatment

- Must be at least 18 years of age

- Must have a Karnofsky Performance Status score of at least 70

- If being treated with steroids, the steroid dose must be stable or decreasing for 1
week prior to randomization

- If being treated with anticonvulsants, must have no change in the type of
anticonvulsants for 2 weeks prior to randomization

- All acute toxic effects (except for alopecia) of any prior treatment must have
resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)

- Baseline laboratory data must be within the following limits: absolute neutrophil
count at least 1500; platelets at least 100,000; hemoglobin at least 9.0 g/dL; serum
creatinine no greater than 1.5 mg/dL, total serum bilirubin no greater than 1.5 times
the upper limit of the normal range; SGOT and SGPT no greater than 2.5 times the upper
limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test
(for females of childbearing potential) negative within 7 days prior to start of study
treatment

- At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at
least 4 weeks since completion of prior temozolomide therapy

- Must have written informed consent

- Must be able and willing to comply with study procedures

- Must have received prior treatment with radiotherapy (conventional fractionated
external beam) and (neo)adjuvant/concurrent chemotherapy (with a temozolomide- or a
nitrosurea-based containing )regimen for GBM

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Must not have received prior treatment (except for surgical debulking) of first
relapse (progression or recurrence) of GBM

- Must not have received prior treatment with another topoisomerase-I inhibitor (e.g.
irinotecan, topotecan, rubitecan)

- Must not have had radiosurgery or radiotherapy within 1 month prior to randomization

- Must not have had prior brachytherapy or chemotherapy wafer implantation

- Must not have had prior high-dose chemotherapy with bone marrow or stem cell support

- Must not receive concomitant treatment with any other investigational agent or
anti-cancer treatment during the study

- Must not be currently enrolled in another therapeutic clinical trial for the treatment
of GBM

- Must not currently (or in the past 5 years) have other malignancies (except for
adequately treated basal cell or squamous cell skin cancer or non-invasive cervical
cancer)

- Must not have any of the following in the past 6 months: myocardial infarction (heart
attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive
heart failure, cerebrovascular accident (stroke), or transient ischemic attack (TIA)

- Must not have had any of the following in the past 2 months: pulmonary embolus (blood
clot in lungs), deep venous thrombosis (blood clot in veins), or other significant
thromboembolic event

- Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or
higher (NCI Common Toxicity Criteria, Version 2.0)

- Must not have known human immunodeficiency virus (HIV) infection

- Must not be pregnant or breastfeeding. Patients (male and female) must be surgically
sterile (or postmenopausal for females) or must agree to use effective contraception
during the period of study treatment

- Must not be inappropriate for entry into the study, in the judgment of the
investigator

NCT00068952
Pfizer
Completed
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
NCT00959946
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma, Glioblastoma, Hepatocellular Carcinoma
NCT01441388
All Genders
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Glioblastoma
  • Drug: Edotecarin
  • Drug: Temozolomide
  • Drug: Carmustine (BCNU)
  • Drug: Lomustine (CCNU)
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
118
March 2006
Not Provided

Inclusion Criteria:

  • Must have biopsy-proven GBM. First relapse (progression or recurrence) of GBM after surgery (or biopsy) and treatment with radiotherapy (conventional fractionated external beam) and chemotherapy (temozolomide- or nitrosurea-based therapy)
  • Must have past biopsy samples available for central pathology review
  • Must have evidence on Gd-MRI of progressive/recurrent disease
  • Must have measurable disease on Gd-MRI obtained within 14 days prior to start of study treatment
  • Must be at least 18 years of age
  • Must have a Karnofsky Performance Status score of at least 70
  • If being treated with steroids, the steroid dose must be stable or decreasing for 1 week prior to randomization
  • If being treated with anticonvulsants, must have no change in the type of anticonvulsants for 2 weeks prior to randomization
  • All acute toxic effects (except for alopecia) of any prior treatment must have resolved or are no greater than grade 1 (NCI Common Toxicity Criteria, Version 2.0)
  • Baseline laboratory data must be within the following limits: absolute neutrophil count at least 1500; platelets at least 100,000; hemoglobin at least 9.0 g/dL; serum creatinine no greater than 1.5 mg/dL, total serum bilirubin no greater than 1.5 times the upper limit of the normal range; SGOT and SGPT no greater than 2.5 times the upper limit of the normal range; albumin at least 3.0 g/dL, serum or urine pregnancy test (for females of childbearing potential) negative within 7 days prior to start of study treatment
  • At least 6 weeks must have elapsed since completion of prior nitrosurea therapy; at least 4 weeks since completion of prior temozolomide therapy
  • Must have written informed consent
  • Must be able and willing to comply with study procedures
  • Must have received prior treatment with radiotherapy (conventional fractionated external beam) and (neo)adjuvant/concurrent chemotherapy (with a temozolomide- or a nitrosurea-based containing )regimen for GBM

Exclusion Criteria:

  • Must not have received prior treatment (except for surgical debulking) of first relapse (progression or recurrence) of GBM
  • Must not have received prior treatment with another topoisomerase-I inhibitor (e.g. irinotecan, topotecan, rubitecan)
  • Must not have had radiosurgery or radiotherapy within 1 month prior to randomization
  • Must not have had prior brachytherapy or chemotherapy wafer implantation
  • Must not have had prior high-dose chemotherapy with bone marrow or stem cell support
  • Must not receive concomitant treatment with any other investigational agent or anti-cancer treatment during the study
  • Must not be currently enrolled in another therapeutic clinical trial for the treatment of GBM
  • Must not currently (or in the past 5 years) have other malignancies (except for adequately treated basal cell or squamous cell skin cancer or non-invasive cervical cancer)
  • Must not have any of the following in the past 6 months: myocardial infarction (heart attack), severe/unstable angina, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident (stroke), or transient ischemic attack (TIA)
  • Must not have had any of the following in the past 2 months: pulmonary embolus (blood clot in lungs), deep venous thrombosis (blood clot in veins), or other significant thromboembolic event
  • Must not have an ongoing cardiac dysrhythmia (abnormal heart rhythm) of grade 2 or higher (NCI Common Toxicity Criteria, Version 2.0)
  • Must not have known human immunodeficiency virus (HIV) infection
  • Must not be pregnant or breastfeeding. Patients (male and female) must be surgically sterile (or postmenopausal for females) or must agree to use effective contraception during the period of study treatment
  • Must not be inappropriate for entry into the study, in the judgment of the investigator
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Austria,   Canada,   Croatia,   Czech Republic,   France,   Germany,   India,   Italy,   Russian Federation,   South Africa,   Spain,   United States
Israel
 
NCT00068952
EDOAGL-8725-001
A5921009
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now